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Abstract
Background: Constitutional loss of function (LOF) single nucleotide polymorphisms (SNPs) in pattern recognition receptors
FPR1, TLR3, and TLR4 have previously been reported to predict oxaliplatin benefit in colorectal cancer. Confirmation of this
association could substantially improve patient stratification.
Methods: We performed a retrospective biomarker analysis of the Short Course in Oncology Therapy (SCOT) and COIN/COIN-B tri-
als. Participant status for LOF variants in FPR1 (rs867228), TLR3 (rs3775291), and TLR4 (rs4986790/rs4986791) was determined by geno-
typing array or genotype imputation. Associations between LOF variants and disease-free survival (DFS) and overall survival (OS)
were analyzed by Cox regression, adjusted for confounders, using additive, dominant, and recessive genetic models. All statistical
tests were two-sided.
Results: Our validation study populations included 2929 and 1948 patients in the SCOT and COIN/COIN-B cohorts, respec-
tively, of whom 2728 and 1672 patients had functional status of all three SNPs determined. We found no evidence of an asso-
ciation between any SNP and DFS in the SCOT cohort, or with OS in either cohort, irrespective of the type of model used. This
included models for which an association was previously reported for rs867228 (recessive model, multivariable-adjusted haz-
ard ratio [HR] for DFS in SCOT¼1.19, 95% confidence interval [CI]¼0.99 to 1.45, P¼ .07; HR for OS in COIN/COIN-B¼0.92, 95%
CI¼0.63 to 1.34, P¼ .66), and rs4986790 (dominant model, multivariable-adjusted HR for DFS in SCOT¼0.86, 95% CI¼0.65 to
1.13, P¼ .27; HR for OS in COIN/COIN-B¼1.08, 95% CI¼0.90 to 1.31, P¼ .40).
Conclusion: In this prespecified analysis of two large clinical trials, we found no evidence that constitutional LOF SNPs in
FPR1, TLR3, or TLR4 are associated with differential benefit from oxaliplatin. Our results suggest these SNPs are unlikely to be
clinically useful biomarkers.
The antitumor immune response is an important determinant
of clinical outcome in colorectal cancer (CRC). To date, attention
has primarily focused on the role of the adaptive immune sys-
tem, and particularly the T-cell response, the increasing inten-
sity of which correlates with reduced recurrence in early-stage
CRC (1,2). Although the influence of the innate immune system
to clinical outcome is less well understood, several studies have
suggested that this may also exert a meaningful antitumor ef-
fect through the recognition of endogenous ligands presented
by dying cells (3–7). This effect has been reported to be espe-
cially relevant in the context of cell death induced by anthracy-
clines and oxaliplatin (3–5), an analog of cisplatin used
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commonly in the systemic therapy of CRC (8). Pattern recogni-
tion receptors present endogenous ligands to macrophages and
as such are essential components of the innate immune re-
sponse (9). Constitutional variants in several genes encoding
these proteins have been shown to alter the innate immune re-
sponse to systemic infection (10). Recently, polymorphisms that
result in putative loss of function (LOF) alterations in pattern
recognition receptor genes have also been reported to influence
benefit from anthracycline and oxaliplatin chemotherapy (4–7).
These variants, which affect FPR1 [rs867228: c.1037A>C,
p.Glu346Ala, where Ala is the LOF allele (11)], TLR3 [rs3775291:
c.1234C>T, p.Leu412Phe, where Phe is the LOF allele (12)], and
TLR4 [rs4986790: c.896A>G, p. Asp299Gly, where Gly is the LOF
allele (4,7)] in strong linkage disequilibrium with rs4986791:
c.1196C>T, p.Thr399Ile, are proposed to act by attenuating the
immune response against the immunogenic cell death caused
by these agents (4–7). These associations were reflected in sta-
tistically significant differences in both progression-free and
overall survival (OS) between patients bearing LOF and func-
tional alleles in these genes when treated with these agents
(hazard ratios [HRs] for LOF allele of 1.37–2.13; summarized in
Supplementary Table 1, available online) (4–7,13,14). If vali-
dated, these variants could be used as biomarkers to target
these toxic therapies to those most likely to benefit from them,
resulting in less harm to patients and cost savings for health-
care providers. Because anthracyclines and oxaliplatin are the
mainstays of systemic treatment against two common cancers
(breast and colorectal, respectively) (15,16) and because these
LOF polymorphisms are relatively common (prevalence of 5% to
80% in populations of European descent), confirmation of this
association could affect many thousands of patients each year
in Europe and the United States alone. The purpose of this vali-
dation study was to confirm this association in the context of
oxaliplatin treatment for CRC by analysis of two well-defined,
prospectively treated cohorts from the Short Course in
Oncology Therapy (SCOT) and COIN/COIN-B trials (17,18),
encompassing both early-stage and advanced disease.
Methods
Clinical Trials
Details of the SCOT (ISRCTN59757862), COIN (ISRCTN27286448),
and COIN-B (ISRCTN38375681) trials have been published previ-
ously (17–20). Briefly, the SCOT trial compared the efficacy of
12 weeks of oxaliplatin-based adjuvant chemotherapy with the
previous standard of care of 24 weeks of treatment in high-risk,
stage II (defined as one or more of: pT4 primary tumor, tumor
obstruction, fewer than 10 lymph nodes harvested, grade 3 his-
tology, perineural invasion, or extramural venous or lymphatic
vascular invasion), or stage III colon or rectal cancer. The trial
randomized 6088 patients between March 2008 and November
2013, of whom 6065 consented for their data to be used for the
intention to treat analyses. At its primary analysis, the attenu-
ated course of chemotherapy was confirmed to be noninferior
to the standard of care (HR¼ 1.01, 95% CI¼ 0.91 to 1.11, test for
noninferiority P¼ .012) (17). As part of the study, participants at
selected centers were invited to participate in a translational
substudy, the TransSCOT study. Tissue and blood samples were
collected from these patients and constitutional DNA was
extracted for translational studies. Following informed consent,
3109 patients provided samples for analysis. The COIN trial ex-
amined both the efficacy of the anti-EGFR monoclonal antibody
cetuximab added to oxaliplatin-based chemotherapy and the
impact of interrupting treatment in patients with stable or
responding metastatic CRC after 12 to 16 weeks of systemic
therapy (18). The trial recruited 2445 patients between March
2005 and May 2008. At its primary analysis, no statistically
significant difference was observed between the
chemotherapy-only and the chemotherapy plus cetuximab
groups (20), and the comparison between intermittent and
continuous chemotherapy failed to confirm noninferiority of
interrupting treatment (18). The COIN-B study compared in-
termittent chemotherapy with either intermittent or continu-
ous cetuximab in 226 patients with metastatic CRC (19).
Among 169 patients with KRAS wild-type disease, analysis
suggested greater activity of continuous cetuximab, though
this difference was not statistically significant. As part of an-
cillary translational studies, 2244 study participants in COIN
and COIN-B donated blood samples for DNA extraction and
analysis. Given their similar patient populations and treat-
ments (21), the COIN and COIN-B biomarker cohorts were
combined for all analyses.
DNA Extraction, Genotyping, and Imputation
DNA was extracted from EDTA-venous bloods using standard
methods. After exclusion of samples that failed DNA extraction
(n¼ 28) and those for which trial IDs were missing or duplicates
(n¼ 14), 3067 DNA samples from the SCOT cohort were geno-
typed using the Global Screening Array (Illumina, San Diego,
CA). Genotyping quality control entailed removal of any sample
or single nucleotide polymorphism (SNP) with more than 2%
missing data, any sample with an outlying heterozygosity rate,
any sample with discordant reported sex and genotype imputed
sex, and any SNP violating Hardy-Weinberg equilibrium at P less
than 1 10–10 (n¼ 66 samples removed; n¼ 32 850 SNPs re-
moved). Identity by descent analysis was conducted in PLINK
1.9 (22) and population stratification was examined using
EIGENSTRAT (23). Related individuals (n¼ 8) were removed
(IBD> 0.185) along with those with non-European ancestry
(n¼ 54, as assessed by merging SCOT with HapMap release 23a
and removing outliers based on eigenvector 1). Genotypes for
2939 remaining individuals were phased using SHAPEIT (24) and
imputed using IMPUTE2 (25) and the UK10Kþ 1000 genomes
merged reference panel. Of the SNPs analyzed in this study,
rs3775291, rs4986790, and rs4986791 were directly genotyped.
The fourth, rs867228, was imputed with an info score of 0.95.
For this imputed SNP, genotype probabilities were converted to
genotypes using gtool (http://www.well.ox.ac.uk/cfreeman/
software/gwas/gtool.html) with a minimum probability thresh-
old of .9 set for specifying per sample genotypes.
Cases from the COIN and COIN-B studies were genotyped us-
ing Affymetrix Axiom Arrays according to the manufacturer’s
recommendations (Affymetrix, Santa Clara, CA) at the King
Faisal Specialist Hospital and Research Center, Saudi Arabia
(under IRB approval 2110033). We excluded individuals from
analysis if they failed one or more of the following thresholds:
overall successfully genotyped SNPs less than 95% (n¼ 122), dis-
cordant sex information (n¼ 8), classed as out of bounds by
Affymetrix (n¼ 30), duplication or cryptic relatedness (identity
by descent >0.185, n¼ 4), and evidence of non-white European
ancestry by principal components analysis-based analysis in
comparison with HapMap samples (n¼ 130). Imputation was
performed using 1000 Genomes Project Pilot data as a reference
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panel (26). Genetic linkage of SNPs was determined by calcula-
tion of D’ and R2 using PLINK 1.9 (22).
Statistical Analyses
Comparison between groups was made using unpaired Student
t test for continuous variables (eg, age) and either v2 or Fisher
exact test for categorical variables (eg, mutation present vs ab-
sent, responder vs nonresponder). Biomarker analyses in this
study were performed and are reported in accordance with the
REMARK guidelines (27). All analyses were prespecified and are
detailed in Supplementary Table 2 (available online). Survival
endpoints included disease-free survival (DFS, defined as time
from study randomization to CRC recurrence or death from any
cause in SCOT only) and OS (defined as time from randomiza-
tion to death from any cause in both cohorts). Progression-free
survival was not used as an endpoint in the COIN/COIN-B trials
in view of the difficulty in defining its duration in the context of
intermittent chemotherapy, which was tested in both studies.
Survival curves for SNP genotypes were plotted using the
Kaplan-Meier method and analyzed by the log-rank test. Survival
endpoints were also analyzed by univariate and multivariable
Cox proportional hazards models, under additive, recessive, and
dominant genetic models (eg, for rs867228, which has alleles A
and C—of which C is the LOF allele—the additive model implies
CC [2] vs CA [1] vs AA [0], modelled as a continuous variable; the
recessive model implies CC [1] vs both CA and AA [0]; and the
dominant model implies both CC and CA [1] vs AA).
Proportionality of hazards was confirmed by inspection of scaled
Schoenfeld residuals. For the multivariable analyses, adjustment
was made for baseline demographic variables (age, sex), clinico-
pathological and molecular covariables of known prognostic
value where available, and treatment type and schedule depend-
ing on the cohort. In the SCOT analyses, these comprised age,
sex, disease site (colon vs rectum), primary tumor stage (pT1–2
vs pT3 vs pT4), nodal status (N0 vs N1 vs N2), treatment regimen
(FOLFOX or CAPOX), and treatment duration (24 vs 12 weeks). In
the COIN/COIN-B analyses, these comprised age, sex, disease site
(colon vs rectum), World Health Organization (WHO) perfor-
mance status (0 or 1 vs 2), primary tumor resection (unresected
vs resected), tumor KRAS, NRAS, and BRAF mutation status (mu-
tated vs wild type), patient white blood cell count (<10 000 cells
per lL vs 10 000 cells per lL), cetuximab treatment (yes vs no),
chemotherapy regimen (FOLFOX vs CAPOX), and chemotherapy
schedule (intermittent vs continuous). In both cases, covariables
were prespecified and no selection procedure (eg, backwards
elimination) was performed. Models included all cases for which
data were available and excluded those with missing data. P val-
ues for individual predictors in Cox models were calculated by
the Wald test. Statistical analyses were performed in R version
3.4.4 (CRAN Corporation) and STATA version 13 (StataCorp,
College Station, TX). All statistical tests were two-sided.
Statistical significance was accepted at P less than .05. No correc-
tion for multiple testing was applied.
Ethical Approval
Informed consent for the collection and analysis of samples
was provided by study participants at the time of study recruit-
ment under trial-specific ethical approval. Molecular analysis of
samples from the SCOT cohort was performed under North
West – Liverpool Central Research Committee approval (17/NW/
0252). Molecular analysis of COIN/COIN-B samples was per-
formed under REC approval (04/MRE06/60).
Results
Patient Characteristics and SNP Genotyping
The CONSORT diagram demonstrating the flow of patients eligi-
ble for this biomarker study is shown in Figure 1. Demographic
Patients randomised 
and consenting to ITT 
analyses:
6065 cases
Blood samples collected 
for DNA extraction: 
3109 cases
DNA extraction and 
genotyping successful: 
2939 cases  
Blood samples not 
collected: 2956 cases
Failed DNA extraction/
genotyping/non-
causasian ancestry 
170 cases
Clinical outcome 
data missing:
10 cases
Clinical outcome data 
available: 2929 cases  
SCOT cohort
Patients randomised:
2445 cases (COIN)
226 cases (COIN-B)
Blood samples collected 
for DNA extraction: 
2368 cases
DNA extraction and 
genotyping successful: 
1950 cases  
Blood samples not 
collected: 303 cases
Failed DNA extraction 
or genotyping: 
418 cases
Clinical outcome 
data missing:
2 cases
Clinical outcome data 
available: 1948 cases  
COIN/COIN-B cohort
Figure 1. CONSORT diagram showing flow of patients analyzed in the study. ITT¼ intention to treat.
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and clinicopathological characteristics of the 2929 SCOT cases
with samples informative for this analysis were broadly similar
to those of the SCOT trial population as a whole, although they
differed statistically significantly, albeit modestly, from the
nonbiomarker population in age, disease site, disease stage, and
nodal status (Supplementary Table 2, available online).
Characteristics of 2244 patients in the COIN/COIN-B biomarker
subgroup were similar to the combined COIN/COIN-B trial popu-
lation (not shown). Details of baseline demographic, clinicopath-
ological, and molecular variables, and SNP genotypes in cases
from both biomarker cohorts are provided in Table 1. Of 2929
patients in the SCOT cohort, 2728 (93.1%), 2924 (99.9%), and 2929
(100%) underwent successful genotyping or imputation and were
informative for analysis of rs867228, rs3775291, and rs4986790/
rs4986791 respectively. The slightly lower number of cases infor-
mative for rs867228 reflects the exclusion of those in which the
genotype could not be imputed with high confidence. The corre-
sponding numbers in the COIN/COIN-B cohort of 1948 patients
were 1672 (85.6%), 1948 (100%), and 1948 (100%) respectively. The
allelic frequencies of all SNPs in both cohorts were concordant
with the reported population frequency in ExAC (28), EVS (29),
and UK10K (30). As expected, rs4986790 and rs4986791 were in
strong linkage disequilibrium in both the SCOT (D’¼ 0.99 and
r2¼ 0.93) and COIN/COIN-B (D’¼ 0.99 and r2¼ 0.89) cohorts.
Because analyses of these two SNPs individually yielded essen-
tially identical results (Supplementary Figure 1, available online),
we largely limited subsequent investigations to rs4986790.
The effect sizes (hazard ratios) of each SNP detectable in
multivariable analyses using recessive and dominant genetic
models, based on a power (1-b) of 0.8 and a two-sided a of 0.05,
are shown for both cohorts in Supplementary Table 4 (available
online). For comparison with previous reports, our power to de-
tect an association of identical effect size using the same (reces-
sive) model to that previously reported for the FPR1 rs867228
SNP was 1.0 and 0.995 for DFS and OS, respectively, in the SCOT
cohort and 1.0 for OS in the COIN/COIN-B cohort. Our power to
detect an association of the same effect size as that previously
reported for the TLR4 rs4986790 SNP using the same (dominant)
model was 0.65 and 0.31 for DFS and OS, respectively, in the
SCOT cohort and 0.96 for OS in the COIN/COIN-B cohort.
Pattern Recognition SNPs and Clinical Outcome in the
SCOT Cohort
Biomarker analyses were performed with data used for the pri-
mary analysis of the SCOT trial, at which point the 2929 patients
Table 1. Baseline characteristics of SCOT and combined COIN/
COIN-B cohorts
Variable
SCOT COIN and COIN-B
PNo. (%) No. (%)
Total 2929 (100) 1948 (100) —
Median age, y (range) 65 (23–84) 53 (18–87) <.001*
Sex
Male 1795 (61.3) 1270 (65.2) <.001†
Female 1134 (38.7) 678 (34.8)
Unknown 0 (0.0) 0 (0.0)
Disease stage
II 585 (20.0) 0 (0.0) —
III 2344 (80.0) 0 (0.0)
IV 0 (0.0) 1948 (100.0)
Unknown 0 (0.0) 0 (0.0)
Primary tumor stage
pT1 94 (3.2) NA —
pT2 285 (9.7) NA
pT3 1694 (57.8) NA
pT4 856 (29.2) NA
Unknown 0 (0.0) NA
Nodal stage
N0 585 (20.0) NA —
N1 1695 (57.9) NA
N2 649 (22.2) NA
Unknown 0 (0.0) NA
Primary tumor location
Colon 2346 (80.1) 1325 (67.9) <.001†
Rectum 583 (19.9) 621 (31.9)
Unknown 0 (0.0) 2 (0.2)
Primary tumor resected
No 0 (0.0) 821 (42.1) —
Yes 2929 (100.0) 1127 (57.9)
Unknown 0 (0.0) 0 (0.0)
Peritoneal metastases
No NA 1519 (78.0) —
Yes NA 259 (13.3)
Unknown NA 170 (8.7)
KRAS mutation status
Wild-type ND 989 (50.8) —
Mutant ND 636 (32.6)
Unknown ND 323 (16.6)
NRAS mutation status
Wild type ND 1506 (77.3) —
Mutant ND 69 (3.6)
Unknown ND 373 (19.1)
BRAF mutation status
Wild type ND 1438 (73.8) —
Mutant ND 143 (7.3)
Unknown ND 367 (18.9)
FPR1 rs867228 genotype
AA 116 (4.0) 49 (2.5) .003†
AC 813 (27.8) 444 (22.8)
CC 1799 (61.4) 1179 (60.5)
Unknown 201 (6.9) 276 (14.2)
TLR3 rs3775291 genotype
CC 1486 (50.7) 934 (47.9) .005†
CT 1207 (41.2) 810 (41.6)
TT 231 (7.9) 204 (10.5)
Unknown 5 (0.2) 0 (0.0)
TLR4 rs4986790 genotype
AA 2581 (88.1) 1744 (89.5) .11†
AG 333 (11.4) 200 (10.3)
GG 15 (0.5) 4 (0.2)
Unknown 0 (0.0) 0 (0.0)
(continued)
Table 1. (continued)
Variable
SCOT COIN and COIN-B
PNo. (%) No. (%)
TLR4 rs4986791 genotype
CC 2568 (90.7) 1726 (88.6) .12†
CT 344 (11.7) 218 (11.2)
TT 17 (0.6) 4 (0.2)
Unknown 0 (0.0) 0 (0.0)
*Determined by two-sided unpaired Student t test. NA¼not applicable; ND¼not
determined; pT¼pathological tumor (T) stage; SCOT¼Short Course in Oncology
Therapy.
†Determined by two-sided v2 test or Fisher exact test in the case of rs4986791 (in
cases of SNP genotypes, values are calculated from cases in which SNP status
was determined).
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in the biomarker cohort had a median follow-up of 36.8 months,
and 538 DFS events and 186 deaths had occurred (Table 2).
Comparing survival curves by the log-rank test, univariate and
multivariable Cox models demonstrated no statistically signifi-
cant association of any SNP irrespective of genetic model im-
posed (Figure 2, Table 2, details of covariables in multivariable
models provided in Supplementary Table 5, available online).
This included models for which an association was previously
reported for rs867228 (5) (recessive model, multivariable-
adjusted HR for DFS¼ 1.19, 95% CI¼ 0.99 to 1.45, P¼ .07) and
rs4986790 (4) (dominant model, multivariable-adjusted HR for
DFS¼ 0.86, 95% CI¼ 0.65 to 1.13, P¼ .27) (Table 2, Supplementary
Table 5, available online).
A previous study reported that the association of the FPR1
LOF polymorphism rs867228 was only evident in patients with
functional TLR3 or TLR4, consistent with their participation in
the same pathway (5). We therefore examined this in the SCOT
biomarker cohort after stratifying by TLR3 (rs3775291) and TLR4
(rs4986790) status. These analyses did not confirm the previ-
ously reported, statistically significant association with DFS in
the context of either functional TLR3 background (multivari-
able-adjusted HR for additive model¼ 1.02, 95% CI¼ 0.82 to 1.27,
P¼ .85; recessive model HR¼ 1.01, 95% CI¼ 0.78 to 1.31, P¼ .91;
dominant model HR¼ 1.09, 95% CI¼ 0.59 to 2.00, P¼ .78) or func-
tional TLR4 background (additive model HR¼ 1.17, 95% CI¼ 0.99
to 1.40, P¼ .07; recessive model HR¼ 1.20, 95% CI¼ 0.98 to 1.48,
P¼ .08; dominant model HR¼ 1.31, 95% CI¼ 0.79 to 1.20, P¼ .30).
Similarly, no statistically significant association of rs867228
with DFS was observed in cases with functional polymorphisms
at both of these loci (multivariable-adjusted HR for additive
model¼ 0.97, 95% CI¼ 0.77 to 1.21, P¼ .76; recessive model
HR¼ 0.92, 95% CI¼ 0.70 to 1.22, P¼ .58; dominant model
HR¼ 1.14, 95% CI¼ 0.60 to 2.16, P¼ .68) (Supplementary Figure 2,
available online).
Pattern Recognition SNPs, Clinical Outcome, and
Oxaliplatin Response in the COIN/COIN-B Cohort
Corresponding analyses were performed on the COIN/COIN-B
cohort in which the median follow-up of the 1948 patients was
23.2 months, by which time 1453 deaths had occurred. Similar
to the SCOT analyses, there was no statistically significant as-
sociation of either SNP with OS by either log-rank test or uni-
variate or multivariable Cox regression, regardless of model
(Figure 3, Table 3, details of covariables in multivariable models
provided in Supplementary Table 6, available online). Again,
this included the recessive model for rs867228 (5) (multivari-
able-adjusted HR for OS¼ 0.92, 95%CI¼ 0.63 to 1.34, P¼ .66), and
the dominant model for rs4986790 (4) (multivariable-adjusted
HR for OS¼ 1.08, 95% CI¼ 0.90 to 1.31, P¼ .40) (Table 3,
Supplementary Table 6, available online). Likewise, prespeci-
fied subgroup analyses stratified by TLR3 and TLR4 status
revealed no evidence of an association between FPR1 status
and OS in the context of functional TLR3 (multivariable-ad-
justed HR for additive model¼ 0.93, 95% CI¼ 0.78 to 1.10,
P¼ .37; recessive model HR¼ 0.91, 95% CI¼ 0.56 to 1.48, P¼ .71;
dominant model HR¼ 0.91, 95% CI¼ 0.74 to 1.12, P¼ .36), or
functional TLR4 (additive model HR¼ 1.03, 95% CI¼ 0.90 to 1.17,
P¼ .66; recessive model HR¼ 1.00, 95% CI¼ 0.68 to 1.49, P¼ .99;
dominant model HR¼ 1.04, 95% CI¼ 0.89 to 1.21, P¼ .62).
Similar to the results from the SCOT cohort, no statistically sig-
nificant association was observed in cases with functional
polymorphisms at both loci (multivariable-adjusted HR for ad-
ditive model¼ 0.99, 95% CI¼ 0.82 to 1.19, P¼ .87; recessive mod-
el¼ 1.22, 95% CI¼ 0.73 to 2.04, P¼ .43; dominant model
HR¼ 0.95, 95% CI¼ 0.76 to 1.18, P¼ .63) (Supplementary Figure
3, available online).
An additional analysis according to radiological response to
oxaliplatin-based chemotherapy after 12 weeks of therapy
Table 2. Univariate and multivariable analyses of DFS and OS in SCOT cohort by LOF SNP*
Polymorphism/genetic model No. DFS events OS events
Univariate analysis Multivariable analysis
DFS OS DFS OS
HR (95% CI) P† HR (95% CI) P† HR (95% CI) P† HR (95% CI) P†
rs867228 (FPR1 c.1037A>C) 2728 487 167
Additive — — — 1.13 (0.96 to 1.32) .15 1.09 (0.83 to 1.44) .53 1.16 (0.98 to 1.37) .08 1.10 (0.84 to 1.47) .48
Recessive — — — 1.15 (0.95 to 1.40) .15 1.07 (0.77 to 1.49) .67 1.19 (0.99 to 1.45) .07 1.10 (0.79 to 1.53) .56
Dominant — — — 1.17 (0.73 to 1.88) .50 1.40 (0.57 to 3.41) .46 1.16 (0.73 to 1.87) .53 1.32 (0.54 to 3.22) .54
rs3775291 (TLR3 c.1234C>T) 2924 536 186
Additive — — — 1.05 (0.92 to 1.19) .52 1.15 (0.93 to 1.44) .29 1.02 (0.90 to 1.17) .68 1.13 (0.91 to 1.41) .27
Recessive — — — 1.24 (0.92 to 1.66) .15 1.46 (0.92 to 2.32) .11 1.14 (0.85 to 1.52) .38 1.32 (0.83 to 2.10) .24
Dominant — — — 1.01 (0.85 to 1.19) .95 1.12 (0.84 to 1.49) .44 1.00 (0.85 to 1.19) .97 1.12 (0.84 to 1.49) .44
rs4986790 (TLR4 c.896A>G) 2929 538 186
Additive — — — 0.92 (0.71 to 1.19) .52 0.89 (0.57 to 1.39) .62 0.89 (0.69 to 1.16) .39 0.87 (0.56 to 1.36) .54
Recessive — — — 1.49 (0.55 to 4.00) .42 1.93 (0.48 to 7.76) .36 1.58 (0.59 to 4.25) .36 1.82 (0.44 to 7.40) .40
Dominant — — — 0.89 (0.67 to 1.17) .40 0.83 (0.51 to 1.35) .45 0.86 (0.65 to 1.13) .27 0.81 (0.50 to 1.32) .39
*Both univariate and multivariable analyses use all informative cases. Hazard ratios show risk associated with reported LOF allele (underscored) for each SNP as fol-
lows: rs867228: FPR1 c.1037A>C p.Glu346Ala; rs3775291: TLR3 c.1234C>T, p.Leu412Phe; rs4986790: TLR4 c.896A>G, p. Asp299Gly. Corresponding associations from
rs4986791 (TLR4 c.1196C>T, p.Thr399Ile), which is tightly linked to rs4986790, were essentially identical to those obtained from analysis of rs4986790 and are not shown.
Multivariable-adjusted HRs were adjusted for age, sex, disease site (colon vs rectum), primary tumor stage (pT1–2 vs pT3 vs pT4), nodal status (N0 vs N1 vs N2), treat-
ment regimen (FOLFOX or CAPOX), and treatment duration (24 vs 12 weeks). Prognostic associations of covariables are shown in Supplementary Table 5 (available on-
line). CI¼ confidence interval; DFS¼disease-free survival; HR¼hazard ratio; LOF¼ loss of function; OS¼overall survival; pT¼pathological tumor (T) stage;
SCOT¼Short Course in Oncology Therapy.
†P values were calculated by two-sided Wald test.
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[complete or partial response vs stable or progressive disease by
RECIST 1.0 (31)] revealed no difference in the proportions of
functional and LOF alleles between responders and nonres-
ponders for rs867228 (P¼ .90, v2 test), rs3775291 (P¼ .68, v2 test),
or rs4986790 (P¼ .64, Fisher exact test).
Discussion
Previous studies have suggested that LOF polymorphisms in the
pattern recognition receptors FPR1 (rs867228), TLR3 (rs3775291),
and TLR4 (rs4986790/rs4986791) decrease the presentation of
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Figure 2. FPR1, TLR3, and TLR4 loss of function (LOF) single nucleotide polymorphisms (SNPs), disease-free survival (DFS), and overall survival (OS) in Short Course in
Oncology Therapy (SCOT) cohort. Kaplan Meier curves showing DFS for patients in SCOT cohort by pattern recognition receptor SNPs rs867228 (FPR1 c.1037A>C
p.Glu346Ala) (A), rs3775291 (TLR3 c.1234C>T p.Leu412Phe) (B), and rs4986790 (TLR4 c.896A>G, p.Asp299Gly) (C) (LOF allele/amino acid underscored in each case).
Corresponding results for OS are shown in D–F. Analyses of the rs4987691 (TLR4 c.1196C>T, p. Thr399Ile) polymorphism, which is strongly linked with rs4986790, were
essentially identical to C and F and are provided as Supplementary Figure 1 (available online). Shaded areas represent 95% confidence intervals. P values indicate com-
parison of all groups by the two-sided log-rank test.
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ligand to the innate immune system by dying cells (3–7). This,
in turn, is proposed to reduce the efficacy of anthracycline and
oxaliplatin chemotherapy, the activities of which depend in
part on the induction of immunogenic cell death (3–5,7). In this
study of nearly 5000 patients with CRC treated with oxaliplatin,
we failed to confirm any of these associations. The 95% confi-
dence intervals for the association of each SNP with DFS and OS
in the SCOT cohort and OS in the COIN/COIN-B cohort all in-
cluded the estimate of no effect. Although our data by no means
exclude an immunomodulatory effect of these SNPs, they sug-
gest that they are very unlikely to be clinically useful as predic-
tive biomarkers for oxaliplatin benefit in CRC. The discordance
between our results and those from previous studies may be
explained by the increased risk of false-positive associations in
the smaller cohorts they used, and in the case of rs867228, an
apparent misclassification of the functional and LOF alleles in
the survival analyses (the functional FPR1 allele c.1037A,
p.346Glu appeared to be incorrectly classified as LOF in all anal-
yses in the study by Vacchelli et al.) (5). Our results underscore
the importance of validation of encouraging findings from mod-
estly sized studies in large, meticulously curated trial cohorts,
even where preclinical data provide a plausible mechanism for
an association.
Strengths of our study include its large size, defined clinical
trial cohorts, standardized therapy, comprehensively annotated
clinicopathological variables, and, in the case of the COIN/
COIN-B cohort, molecular variables and mature outcome data.
Consequently, our analyses were powered to detect even a
modest association of most SNPs with clinical outcome and had
a power of greater than 0.95 to detect an association of similar
strength to that previously reported for the rs867228 and
rs4986790 LOF variants (4,6). Limitations include the lack of mo-
lecular profiling in the SCOT trial, which meant that we were
unable to test for an association of the SNPs with clinical out-
come in specific tumor subgroups such as those with enhanced
immunogenicity due to defective DNA mismatch repair or POLE
exonuclease domain mutation.
In summary, in this study of two large clinical trial cohorts,
we find no evidence that LOF SNPs in the pattern recognition
receptors FPR1, TLR3, and TLR4 are associated with differential
benefit from oxaliplatin in CRC. Future studies may better de-
fine the complex relationship between cytotoxic therapeutic-
induced cell death, pattern recognition SNPs, and the innate im-
mune system.
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Figure 3. FPR1, TLR3, and TLR4 loss of function (LOF) single nucleotide polymor-
phisms (SNPs) and overall survival (OS) in COIN/COIN-B cohort. Kaplan Meier curves
showing OS for patients in combined COIN/COIN-B cohort by pattern recognition re-
ceptor SNPs rs867228 (FPR1 c.1037A>C p.Glu346Ala) (A), rs3775291 (TLR3 c.1234C>T
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P values indicate comparison of all groups by the two-sided log-rank test.
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